Weng I. Ng

Nov 20, 2024 | onlinelibrary.wiley.com | Udit Nindra |Rhiannon Mellor |Weng I. Ng |Gowri Shivasabesan

Data Availability Statement The data sets for this manuscript are not publicly available, but requests to access the data sets should be directed to Udit Nindra ([email protected]).

Aug 20, 2023 | mdpi.com | Stephanie Lim |Wei Ling Chua |Weng I. Ng |Emilia Ip

1. IntroductionA standard treatment for locally advanced rectal cancer (LARC) is trimodality therapy, consisting of neoadjuvant radiation +/− chemotherapy, surgery, and adjuvant chemotherapy. Despite trimodality therapy, around a third of patients still develop recurrent disease [1]. Currently, there are no biomarkers in routine clinical practice for patients with LARC to personalise treatment.